-

SHAREHOLDER ALERT: Robbins LLP Announces that InnovAge Holdings Corp. (INNV) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired InnovAge Holdings Corp. (NASDAQ: INNV ) securities pursuant to the Company's March 2021 initial public offering ("IPO"), for violations of the Securities Act of 1933. InnovAge operates a healthcare delivery platform that purports to take a "patient-centered care approach" to improve the quality of care that participants receive.

If you suffered a loss due to InnovAge Holding Corp.'s misconduct, click here.

InnovAge Holdings Corp. (INNV) Misstated its Operational and Business Prospects in its Offering Documents

According to the complaint, on March 5, 2021, InnovAge conducted its IPO, selling its shares at $21.00 per share for proceeds of approximately $373.6 million. On September 21, 2021, InnovAgre revealed that the Centers for Medicare and Medicaid Services had "determined to freeze new enrollments at [the Company's] Sacramento center based on "deficiencies detected in [a recent] audit." It stated that these "deficiencies relate to failures to provide covered services, provide accessible and adequate services, manage participants' medical situations, and oversee use of specialists, among others." On this news, the stock price fell $2.90 per share, or 25%, to close at $8.75 per share on September 22, 2021. The stock now trades at just $6.30 per share, a significant decline from the $21 per share IPO price.

If you purchased shares of InnovAge Holdings Corp. (INNV) pursuant to the Company's March 5, 2021 IPO, you have until December 13, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against InnovAge Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:INNV

Release Summary
InnovAge Holdings Corp. (INNV) Misstated its Operational and Business Prospects in its Offering Documents
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

LKQ Corporation Class Action Reminder - Robbins LLP Encourages LKQ Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired LKQ Corporation (NASDAQ: LKQ) common stock between February 27, 2023 and July 23, 2025. LKQ is a global distributor of alternative collision replacement parts, recycled engines, and other vehicle components for the repair of automobiles.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.Wha...

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...
Back to Newsroom